Text word count = 5339 24 2 Abstract 25 Clostridium difficile infection (CDI) is a major public health threat worldwide. The use of 26 nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with enhanced susceptibility to and 27 severity of nosocomial CDI; however, the mechanisms driving this phenomenon have not been 28 elucidated. NSAIDs alter prostaglandin (PG) metabolism by inhibiting cyclooxygenase (COX) 29 enzymes. Here, we found that treatment with the NSAID indomethacin prior to infection altered 30 the microbiota and dramatically increased mortality and intestinal pathology associated with CDI 31 in mice. We demonstrate that in C. difficile-infected animals, indomethacin lead to PG 32 deregulation, an altered proinflammatory transcriptional and protein profile, and perturbed 33 epithelial cell junctions. These effects were paralleled by an increased recruitment of intestinal 34 neutrophils and CD4 + cells. Together, these data implicate NSAIDs in perturbation of the gut 35 microbiota and disruption of protective COX-mediated PG production during CDI, resulting in 36 altered epithelial integrity and associated immune responses. 37
4 mice when the NSAID was applied following inoculation and throughout the infection (Muñoz-64 Miralles et al., in press, Future Microbiology, 2018) , and indomethacin exposure is associated 65 with alterations in the structure of the intestinal microbiota (12, 13) . NSAIDs are among the most 66 highly prescribed and most widely consumed drugs in the United States(14), particularly among 67 older adults(15) and have been implicated in causing spontaneous colitis in humans (16, 17) . 68
They act by inhibiting cyclooxygenase (COX) enzymatic activity, which prevents the generation 69 of prostaglandins (PGs) and alters the outcome of subsequent inflammatory events. 70
Prostaglandins, and among those especially PGE2, are important lipid mediators that are highly 71 abundant at sites of inflammation and infection, and support gastrointestinal homeostasis and 72 epithelial cell health (18) . NSAID use has been associated with shifts in the gut microbiota, both 73 in rodents and humans (19) (20) (21) (22) , but these shifts have not been explored in the context of CDI. 74
In this report, we deployed a mouse model of antibiotic-associated CDI to examine the 75 impact of exposure to indomethacin prior to infection with C. difficile on disease severity, 76 immune response, intestinal epithelial integrity, and the gut microbiota. These investigations 77 revealed that even a brief exposure to an NSAID prior to C. difficile inoculation dramatically 78 increases CDI severity, reduces survival, and increases pathological evidence of disease. 79 Inhibition of PG biosynthesis by indomethacin altered the cytokine response and immune cell 80 recruitment following CDI, enhancing intestinal tissue histopathology and allowing a partial 81 systemic bacterial dissemination by dismantling intestinal epithelial tight junctions. Additionally, 82 indomethacin treatment alone significantly perturbed the structure of the gut microbiota. These 83 findings support epidemiological data linking NSAID use and CDI, and caution against the 84 overuse of NSAIDs in patients at high risk for C. difficile, such as older adults. 85
Results

86
Indomethacin worsens C. difficile infection in mice and increases mortality 87
To determine the extent to which pre-exposure to NSAIDs influences the natural course 88 of CDI, mice were treated with indomethacin for two days prior to inoculation with C. difficile 89 ( Fig. 1A) . We infected C57BL/6 female mice with 1x10 4 spores of the C. difficile NAP1/BI/027 90 strain M7404 following 5 days of pre-treatment with the broad-spectrum antibiotic, cefoperazone 91 ( Fig. 1A) . This brief indomethacin treatment prior to CDI dramatically decreased cecum size, 92 increased mortality rate from 20% to 80% (Fig. 1C ) but did not significantly impact weight loss 93 ( Fig. 1D ). Mice pre-treated with indomethacin and infected with C. difficile also displayed more 94 severe histopathological evidence of cecal tissue damage compared to mice infected with C. 95 difficile that were not exposed to the drug (Fig. 1E ). Indomethacin-exposed and infected mice 96 exhibited no change in the burden of C. difficile in the cecum (Fig. 1F ), but their livers harbored 97 significantly greater loads of mixed aerobic and anaerobic bacteria ( Fig. 1G ), suggesting that 98 indomethacin pre-treatment compromised intestinal barrier function during CDI and fostered 99 microbiota translocation to the liver. 100 7 To further characterize the impact of NSAIDs on the immune response during CDI, we 138 explored the impact of indomethacin on intrinsic mechanisms of host defense in the 139 gastrointestinal tract. Specifically, we focused on the Gram-positive selective antimicrobial 140 peptide, REG3γ, and mucin; two host intestinal defense factors that have been shown to be 141 important for the control of gastrointestinal infections(30). We confirmed by qRT-PCR that CDI 142 upregulated Reg3g transcription, while Muc2 transcript levels were not significantly altered 143 following indomethacin treatment ( Fig.3E ). To evaluate if PGE2 synthesis and signaling were 144 altered due to infection or indomethacin treatment, we analyzed the expression of genes 145 encoding PGE2 receptors and the enzymes involved in PGE2 metabolism. The transcription of 146 the PGE2 receptor gene Ptger4 was severely suppressed upon CDI, but indomethacin did not 147 significantly exacerbate this suppression ( Fig. 3F ). Infection C. difficile suppressed colonic 148 expression of the COX-1 and COX-2 encoding genes Ptgs1 and Ptgs2, respectively ( Fig. 3G) . 149
Notably, indomethacin pre-treatment prevented this down-modulation and simultaneously 150 induced the expression of the Ptges gene, which encodes a major synthase for PGE2 ( Fig. 3G) . 151
What is more, indomethacin further reduced expression of the PGE2 inactivating enzyme 15-152 hydroxyprostaglandin dehydrogenase (Hpgd gene; Fig. 3G ). This selective inhibition of Ptgs1 153 and Ptgs2 transcription, together with inhibition of Hpgd and enhanced Ptges are consistent with 154 the paradoxical increase in PGE2 concentrations observed 72 hours following infection ( Fig. S1 ). 155
Together, these data demonstrate that indomethacin pre-treatment increases innate immune 156 cell activation and recruitment, while also leading to PG dysregulation. 157
158
Indomethacin increases intestinal inflammation by upregulating a combined myeloid-159 recruitment and response in the cecum 160
Following the observation that indomethacin pre-treatment significantly altered cellular 161 and transcriptional immune responses during CDI, we sought to determine the impact of this 162 drug on tissue-level inflammatory protein expression during infection. Infected mice (either 163 exposed to indomethacin or not) were euthanized and ceca were harvested at day 3 post-CDI. 164
Whole tissue homogenates were used to measure the concentration of a panel of inflammation-165 related proteins and were normalized to total protein content per cecum (Fig. 4 ). The protein 166 levels observed largely supported the transcriptomics results from our previous results, 167
confirming what has already been reported for CDI regarding IL-1β and immune mononuclear 168 cell recruitment and activation proteins like CCL3, CXCL2 and CCL4. Interestingly, IL-6-class 169 cytokines (IL-6, LIF) were among the most enhanced by indomethacin pre-treatment, consistent 170 with what has been found in humans infected with C. difficile (24, 31, 32) . Together with the 171 increase in IL-1β, and consistent with the above results showing enhanced Th17 responses, 172 these data implicate an exacerbated IL-17A-related response caused by indomethacin. In 173 contrast, some type-1-associated inflammatory molecules like IL-12p40 were downregulated by 174 indomethacin pre-treatment. 175 176
Indomethacin perturbs colonic epithelial cell junctions of C. difficile-infected mice 177
The observations describing the increased bacterial translocation ( Fig. 1G ), together 178 with the increased local PGE2 levels ( Fig. 1H ) and inflammatory molecules ( Fig. 3 ), lead us to 179 investigate whether the integrity of the intestinal epithelial barrier was compromised due to 180 indomethacin pre-treatment during CDI. We assessed the impact of indomethacin on the 181 integrity of colonic epithelial junctions of C. difficile-infected mice via transmission electron 182 microscopy and immunofluorescence staining of tight junction (TJ) and TJ-associated proteins. 
Indomethacin alters the intestinal microbiota composition without further reducing 200 microbial community diversity after antibiotic treatment 201
The composition of the gut microbiota has a profound impact on the 202 manifestation and clearance of CDI, as well as the virulence of C. difficile and the outcome of 203 disease(33, 34). There is also evidence suggesting prominent off-target effects of 204 pharmaceutical agents, such as NSAIDs, on the gut microbiota and gastrointestinal health (20, 205 35) . To examine the impact of indomethacin on the murine gut microbiota, mice were treated 206 with a two-day course of indomethacin and the microbial community was subsequently 207 surveyed using 16S rRNA gene sequencing. One day post-treatment, mice given indomethacin 208 showed no significant alteration in α-diversity ( Fig. S2 ) but exhibited a significant shift in 209 community structure compared to untreated mice (P<0.001; AMOVA) ( Fig. 6A ). To characterize 210 differentially abundant taxa in indomethacin treated mice, we utilized the biomarker discovery 211 impact of indomethacin on the murine gut microbiota, we collected samples periodically for 11 218 days following administration of indomethacin. We observed significant differences in 219 community structure up to 2 days following administration of indomethacin treatment and a 220 significant enrichment of Bacteroides (OTU 1) could be detected as far as 11-days following 221 treatment with indomethacin ( Fig. 6C ). Next, to determine how indomethacin may impact the 222 microbiota in the context of antibiotic treatment, mice were again exposed to indomethacin for 2 223 days following 5 days of cefoperazone (0.5 mg/ml) treatment. Although cefoperazone treatment 224 dramatically reduced overall community α-diversity in all mice, we detected significant 225 alterations in community structure associated with co-treatment with indomethacin and 226 cefoperazone that could be observed 11-days post-treatment ( Fig. 6D; Fig. S3 ). Initial 227 differences in microbial community structure were driven by a significant bloom in Paenibacillus 228 (OTU 11), while Akkermansia (OTU 6) was significantly enriched in mice treated with 229 indomethacin and cefoperazone on day 11 post-treatment ( Fig. 6 .E-F). Together these data 230
suggest that indomethacin has a marked effect on the structure of the gut microbiota and these 231 off-target effects likely contribute to disease exacerbation during CDI. 232 11 Discussion 233 CDI is the most commonly diagnosed cause of antibiotic-associated diarrhea and has 234 surpassed methicillin-resistant Staphylococcus aureus as the most common healthcare 235 associated infection in many US hospitals(36). Nearly 30,000 people die each year in the US 236 from CDI (37). A major challenge of CDI is recurrence, which can impact 20-30% of patients 237 and is associated with an increased risk of death(4, 38). One of the most promising treatments 238 for CDI is fecal microbiota transplantation (FMT), which is estimated to be >80% effective in 239 most studies (39, 40) . However, problems with standardization, availability, and putative risks 240 from FMT have made this form of therapy suboptimal(41). There continues to be a demand for 241 effective approaches to limit CDI severity and to understand complications arising from the 242 synergy of CDI with intestinal immune responses and drugs used to limit damaging 243 inflammatory effects. 244
245
The NSAIDs are among the most commonly prescribed drugs in the US with more than 246 98 million prescriptions filled annually (14), and an estimated 29 million Americans using over-247 the-counter NSAIDs per year(42). As they prevent synthesis of endogenous PGs, NSAIDs can 248 adversely affect intestinal health. Epidemiological studies reveal an association between CDI 249 risk and the use of NSAIDs, underscored by a recent meta-analysis(11). The plausibility of a link 250 between NSAID use and CDI is bolstered by the association between NSAID use and flare-ups 251 of inflammatory bowel disease and the occasional occurrence of NSAID-induced colitis (43) (44) (45) (46) . 252
Recent mouse studies have established that concomitant NSAID use exacerbates active CDI 253 (Muñoz-Miralles et al., in press, Future Microbiology, 2018) . 254
255
Animal and human studies suggest that CDI induces local and systemic increases in 256
PGs such as PGE2 (47). Prostaglandin E2 is one of the most common and well-characterized 257
PGs, which has long been known to have major effects on gastrointestinal health(48-51). COX-258 1-dependent production of PGE2 is gastroprotective, explaining why chronic NSAID use is 259 associated with stomach ulcers, and why such ulcers can be prevented by administering the 260 FDA-approved oral PGE analogue misoprostol to NSAID-treated patients(52). In addition, 261 endogenous PGE2 production prevents gut epithelial cell death and promotes colonic tumor 262 growth by directly inducing tumor epithelial cell proliferation, survival, and 263 migration/invasion (52) (53) (54) . It is also possible that PGE2 modulates disease through alteration of 264 the microbiome, as NSAIDs have been implicated as potentially disrupting the gut 265 microbiome(20, 55). Additionally, PGE2 functions as a key inflammatory signal that can regulate 266 certain immune responses, with its local levels being tightly regulated during the trigger but also 267 the resolution of inflammatory processes(56-58). Some of the best-known functions of PGE2 268 are indeed its role in intestinal inflammation and cancer, as well as its impact on the immune 269 system(18). Paradoxically, we observed that pre-treatment with the COX inhibitor indomethacin 270 caused a dysregulation of PG metabolism that led to increased PGE2 production upon CDI. This 271 heightened PGE2 response was associated with elevated intestinal inflammatory cytokines, 272 monocyte and neutrophil recruitment, partial dismantling of the intestinal epithelial cells tight 273 junctions, and a specific disturbed microbiota composition. 274
275
Immune protection against C. difficile challenge seems to be independent of CD4 + cells, 276
anti-toxin IgG and pIgR(59), but it strongly relies on rapid and effective myeloid cell responses 277 (9, 37, 60). Cells of the immune system can exert critical roles in controlling bacterial pathogen 278 damage and intestinal health through production of damaging or protective cytokines by T cells 279 or Innate Lymphoid Cells (ILCs)(61, 62). Production of IFNγ by T cells and neutrophils has a 280 protective role against CDI(63, 64), and the associated production of IL-12 by innate cells upon 281 CDI can have a strong positive feedback effect on IFNγ production in this context. The role of 282 IL17 cytokines and their cellular sources is more controversial, as they can induce damage but 283 also trigger intestinal repair processes and maintain barrier integrity(65, 66). Perturbation of the 284 13 microbiota induced by antibiotic treatment can also cause an imbalance of protective Treg:Th17 285 ratios(67). ILCs are however critical for controlling the acute response induced by CDI. In 286 contrast to Rag1 -/mice, Rag2 -/-Il2rγ -/mice rapidly succumb to CDI. While ILC3s display a 287 limited role to resistance, loss of IFNγ expressing ILC1s in Rag1 -/mice increased 288 susceptibility (7). The contribution to CDI pathogenesis by other highly relevant cytokines like IL-289 23 and IL-22 provided by innate immune cells strongly depends on context (23, 24, 37, (68) (69) (70) . 290
In our studies, we found that indomethacin pre-treatment prior to CDI increased local levels of 291 chemokines that induce recruitment of inflammatory myeloid cells like CXC2, CCL3 and CCL4, 292 with a concomitant increase in circulating and local neutrophils numbers while type 3 ILC were 293 unaltered. Also, in coordination with the increased levels of intestinal IL-6 and IL-1β, total CD4 + 294 cells and CD4 + RORγt + cells were found in larger numbers in the colonic lamina propria but not 295 the draining mesenteric lymph nodes. 296
297
Intestinal epithelial cells constitute the main barrier against infectious agents colonizing 298 the gastrointestinal tract. Cell junctional complexes, notably the tight junctions, regulate 299 paracellular permeability and restrict the translocation of luminal microbes and microbial 300 products across the epithelial monolayer(71). Displacement of occludin, but not ZO-1, from the 301 junctions of mouse colonic epithelial cells during CDI did not manifest as gross morphological 302 changes of TJ regions during EM visualization. This is reminiscent of the alterations seen in 303 anti-CD3-, and TNF-α-treated mice, respectively, and consistent with the view that occludin is a 304 regulator, rather than a key structural component, of TJs(72). However, indomethacin 305 pretreatment with CDI redistributed both occludin and ZO-1 to the cytosol, and electron 306 micrographs revealed a concomitant loss of TJ interactions. These changes are expected to 307 increase paracellular permeability and promote bacterial translocation and could explain the 308 observed increase in bacterial burden in the livers of indomethacin-treated, C. difficile-infected 309
animals. 310
Induction of severe colitis upon CDI is subordinated to alterations in their microbiota 312 caused by antibiotic administration that lead to dismantling of colonization resistance (5, 33, 37, 313 73, 74) . Interestingly, recent studies have begun to highlight previously underappreciated and 314 potentially detrimental effects of pharmaceutical drugs, such as NSAIDs, on the gut 315 microbiota (20, 35) . We observed that indomethacin did not cause an alteration of the microbial 316 α-diversity but did induce significant alterations in microbiota structure that lead to an 317 enrichment of Bacteroides, Akkermansia, Porphyromonadaceae, and Parasutterella, and a 318 decrease in Turicibacter and Porphyromonadaceae. Interestingly, increases in Bacteroides and 319
Akkermansia have been reported in association with inflammatory bowel disease and other 320 infections(75-78). Furthermore, Turicibacter has been shown in several studies to be 321 associated with colonization resistance to C. difficile (6, 79) . Thus, indomethacin-mediated 322 alterations in the microbiota may have a profound impact on manifestation and severity of CDI. 323
Interestingly, when the microbiota α-diversity was severely reduced by antibiotic treatment, we 324 found that Paenibacillus and Akkermansia expanded in mice pretreated with indomethacin. At 325 present, the role of Paenibacillus in the pathology of CDI is unknown and further investigation is 326 warranted. 327 328 Injury to intestinal epithelial barriers and microbial translocation can lead to a systemic 329 response that mimics some aspects of sepsis and unveils a massive release of inflammatory 330 cytokines, like IL-1β, and increases neutrophil and macrophage recruitment and activation (24). 331
It is still unclear how the innate and adaptive arms of the immune response coordinate during 332 CDI, especially in situations like the one we present with pre-treatment with indomethacin. In 333 such circumstances, it is important to note that Type 3 ILCs can dysregulate adaptive immune 334 CD4 + cell responses against commensal bacteria, but this ILC-mediated regulation of adaptive 335 immune cells occurred independently of interleukin (IL)-17A, IL-22 or IL-23, but is dependent on 336 antigen presentation(80). Additionally, antibiotics alone can promote inflammation through 337 goblet cell-mediated translocation of native colonic microbiota in mice(81), but CDI induces 338 significant goblet cell loss(82), which would counter effect this bacterial translocation in the 339 experimental conditions such as those described in this work. 340
341
Our results highlight the capacity of a short-term oral dose of the NSAID indomethacin to 342 cause an imbalance in PG production and disrupt the intestinal barrier to allow for bacterial 343 entrance in the bloodstream. These effects are paralleled by a specific disarrangement of the 344 intestinal microbiota and dysregulated inflammatory and immune responses that lead to 345 increase pathological damage and finally unfold in an increased mortality rate. Our results call 346 for caution in the use of NSAIDs in the context of C. difficile infections, but also potentially when 347 other intestinal pathogens or insults co-occur with acute inflammatory events that affect PG 348 balances. Moreover, we also highlight how a temporary modification of a set of key 349 inflammatory mediators like PGs in the host can lead to significant perturbations to the resident 350 gut microbiota. We believe that this unique combination of effects caused by indomethacin and 351 CDI in the host and their microbiota could represent a generalized mechanism that leads to 352 increased intestinal damage and complications when NSAIDs, or other drugs that alter key 353 inflammatory molecules with pleiotropic effects, are used. 354
Materials and Methods
355
Experimental animals and infection model 356
All mice used in this study were obtained from Jackson laboratories (C57 BL6J) and were 357 females of 6 weeks of age at arrival. Mice were given 2 weeks' time to adapt to the new facilities 358 and avoid stress associated responses and allow for in-house conditions adaptations. Mice 359 were given Cefoperazone at 0.5 mg/ml in drinking water ad libitum for 5 days prior to treatment 360 with Indomethacin (Cayman Chemical) at 10 mg/kg or vehicle (PBS) for 2 consecutive days by 361 oral gave and then infected or not with 1x10 4 spores of Clostridium difficile (NAP1/BI/027 strain 362 
Bacterial burden in mouse organs 381
Liver was collected from the mouse with sanitized instruments and immediately placed in 1 mL 382 of PBS in a 12 well plate. After the tissue was minced with scissors, 20 mL of the supernatant 383 was drawn off and serially diluted. Dilutions were plated on TCCFA plates under aerobic and 384 anaerobic conditions. After 24 hours, the plates were collected, CFUs were calculated and 385 normalized to the weight of the liver. Cecum was also collected using sanitized instruments, and 386 contents were expelled by placing pressure on the organ with a scalpel. Contents were then 387 collected and put into a 1.5 ml tube. Weight of the contents was recorded, PBS was added, 388 vortexed, and the slurry was serially diluted and plated onto TCCFA plates (Anaerobe Systems). 389
After 24 hours, CFUs were counted and normalized to the weight of each sample. 390 391
Tissue protein quantification and multiplex 392
Total cecum protein was isolated from ceca pre-washed with ice-cold PBS, homogenized a 393 tissue shredder (Tissuemiser) and then centrifuged for 3 min at 8,600 g. Supernatants of these 394 preparations were submitted for Luminex analysis of the provided analytes using x-map 395 technology via the MapgPix® system, in combination with multiplex kits from Millipore Sigma. 396
Total tissue protein content was quantified by DC assay. Data was analyzed with GraphPad 397 Prism 6.0, and heat maps were generated using the Morpheus software from the Broad Institute 398 (https://software.broadinstitute.org/morpheus/). 399 400
Flow cytometry 401
Cell suspensions from the mesenteric lymph nodes, peritoneal lavage and colon lamina propria 402 from euthanized mice were obtained from mice at the indicated time points. Cell suspensions 403
were incubated with Fc-block for 15 minutes on ice and then surface stained with a cocktail 404 containing monoclonal anti mouse antibodies containing anti-CD19 (1D3), CD8a (5H10-1), anti-405 CD49b (DX5), anti-CD11b (M1/70), anti-CD11c (N418) and anti-CD196 (x29-2I.17) from 406
Biolegend as well as anti-CD4 (RM4-5) and anti-Ly6G (1A8) from BD. After 30 minutes 407 incubation on ice, cells were washed, fixed and permeabilized using the FoxP3 Fix/Perm buffer 408 kit from eBiosciences/ThermoFisher and intracellular staining for RORt (clone Q31-378) was 409 performed as a last step. Flow cytometry data was obtained with BD FACSDiva TM 7.0 software 410 and .fcs 3.0 files analyzed with FlowJo TM . 411 412
Electron and Immunofluorescence microscopy 413
Colonic tissue samples were fixed and stored in Karnovsky's solution (4% paraformaldehyde in 414 PBS (pH 7.4) with 1% glutaraldehyde) for at least 24 hrs at 4°C. Samples were neutralized with 415 125 mM glycine in PBS, post-fixed in 1% osmium tetroxide, and sequentially dehydrated with 416 15%, 30%, 50%, 70%, 90% and 100% ethanol. Samples were then infiltrated with Spurr's Resin 417 (Electron Microscopy Sciences, Hatfield, PA). Ultra-thin sections were contrasted with 2% 418 uranyl acetate, followed by Reynold's lead citrate and visualized with an FEI Tecnai Spirit 419 transmission electron microscope (FEI, Hillsboro, OR) equipped with AMT CCD camera and 420 AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, MA). 421
For immunofluorescence microscopy tissue samples were frozen in OCT embedding medium 422 (Tissue-Tek, Sakura Finetek, CA) and stored at −80°C. OCT-mounted tissue samples were 423 sectioned at 3 μM thickness and fixed in 4% paraformaldehyde in PBS (pH 7.4) for 20 minutes 424 at room temperature. Samples were washed with PBS, permeabilized with 0.2% Triton X-100 in 425 PBS, quenched with 50 mM NH4Cl in PBS and then blocked with 5% IgG-free bovine serum 426 albumin (BSA) in PBS. Primary antibodies used were 1:50 dilution of rabbit anti-occludin and 427 rabbit anti-ZO1 (Abcam, Cambridge, MA). Samples were incubated with primary antisera 428 overnight at 4C, and then washed three times with 1% IgG-free BSA in PBS. Secondary 429 antibodies (Alexa Fluor 555-conjugated anti-rabbit IgG) were added at 8 μg/ml in 5% IgG-free 430 BSA for 1 hour. Samples were washed with PBS, stained with 4,6-diamidino-2-phenylindole 431 (DAPI) and mounted in ProLong Diamond Antifade reagent (Thermo Fisher Scientific, Waltham, 432 Pittsburgh, PA) equipped with Olympus 100X/1.40 oil objective and using immersion oil 434 (n=1.516) and GE Healthcare Software Version 6.5.2. ImageJ 1.51j8 (National Institutes of 435
Health, Bethesda, MA) was used to merge and pseudocolor images. 436 437
Colon histology and pathology scoring 438
Colons from experimental mice were collected at day 3 post-infection, then flushed with cold 439 PBS, open longitudinally and rolled to generate swiss rolls. This colon rolls were fixed for 5 days 440 in 10% buffered Formalin Phosphate and then transferred to 70% ethanol for 7 days. After that, 441
these Swiss rolls were used to generate paraffin blocks that were stained with H&E and scored 442
for the degree of injuries as described in Theriot CM et al., Gut Microbes 2:6, 326-34. 2011. 443 
444
DNA extraction, 16S rRNA gene sequencing, and gut microbiota analyses 445
Fecal samples were collected fresh from individual mice at prior to (baseline) and following 446 treatment with cefoperazone, indomethacin, or a combination of cefoperazone and 447 indomethacin. In a subset of mice (N=6/group), fecal samples were collected for the time 448 course of a post-treatment 11-day recovery period. Following collection, fecal samples were 449 immediately put on ice and subsequently frozen for storage at −20 °C. Microbial genomic 450 DNA was extracted using the 96-well PowerSoil DNA isolation kit (Qiagen). For each 451 sample, the V4 region of the bacterial 16S rRNA gene was amplified and sequenced using 452 the Illumina MiSeq Sequencing platform as described elsewhere (Kozich et al., 2013) . 453
Sequences were curated using the mothur software package (v1.40.3) as previously 454 described (Zackular et al., 2016; Schloss et al., 2009; Kozich et al., 2013) . Briefly, the 455 workflow we used included generating contigs with paired-end reads, filtering low quality 456 sequences, aligning the resulting sequences to the SILVA 16S rRNA sequence database, 457 and removed any chimeric sequences flagged by UCHIME. Following curation, we obtained 458 20 between 9 and 83,525 sequences per sample (median = 13,161.5), with a median length of 459 253 bp. To minimize the impact of uneven sampling, the number of sequences in each 460 sample was rarefied to 4200. Sequences were clustered into OTUs based on a 3% distance 461 cutoff calculated using the OptiClust algorithm. All sequences were classified using t he 462
Ribosomal Database Project training set (version 16) and OTUs were assigned a taxonomic 463 classification using a naive Bayesian classifier. Significantly altered OTUs for each group 464
were selected using the biomarker discovery algorithm LEfSe (linear discriminant analysis 465 (LDA) effect size) in mothur (Segata et al., 2011) . α-diversity was calculated using the 466 Shannon diversity index and β-diversity was calculated using the θYC distance metric with 467 OTU frequency data. FASTQ sequence data obtained in this study has been deposited to the 468 Sequence Read Archive (SRA) at NCBI under the accession number SRP152292. Mice were treated as previously described and were euthanized 3 days after infection. The 704 colon lamina propria (cLP), mesenteric lymph nodes (mLN) and peritoneal cavity (Per.Cav.) 705 were collected for analysis by flow cytometry (n = 8-10/group). (A) Representative flow plots 706 from d3 CDI mice infected but not treated with indomethacin depicting the gating used to identify 707 neutrophils (Lin + Ly6G + ), CD4+ T cells (Lin -CD4 + ) and ILC group3 cells (Lin -Ly6G -CD4 -RORγt + ) 708 in different organs. (B) Neutrophils and (C) CD4+ T cells numbers (x10 6 ). Quantification of the 709 analysis of mLN and cLP CD4 + RORγt + Th17 cells (D) and ILC type 3 (Lin -CD3ε -RORγt + ) cells 710 (E). The middle line is presented as average. One-way ANOVA with Turkey's correction was 711 used to evaluate significant differences among all groups: *P<0.05, **P<0.01, ***P<0.001. 712 713
